NADAC acquisition cost data for AMLODIPINE-ATORVAST 10-10 MG. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00378451793 | $1.09 | 2022-12-21 | Rx |
| 43598032130 | $1.09 | 2022-12-21 | Rx |
| 43598032190 | $1.09 | 2022-12-21 | Rx |
| 59762673001 | $1.09 | 2022-12-21 | Rx |
| 60505347903 | $1.09 | 2022-12-21 | Rx |
| 66993027030 | $1.09 | 2022-12-21 | Rx |
| 00378451793 | $1.09 | 2022-12-21 | Rx |
| 43598032130 | $1.09 | 2022-12-21 | Rx |
| 43598032190 | $1.09 | 2022-12-21 | Rx |
| 59762673001 | $1.09 | 2022-12-21 | Rx |
Generic: Amlodipine/Atorvastatin | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $28.5M | 97,932 | 24,663 | $4.16 |
| 2020 | $27.5M | 97,047 | 24,281 | $3.94 |
| 2021 | $26.1M | 96,192 | 24,706 | $3.72 |
| 2022 | $26.0M | 96,507 | 24,884 | $3.67 |
| 2023 | $25.3M | 97,210 | 25,230 | $3.61 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| New Jersey | $2.0M | 6,632 | 1,847 |
| Florida | $1.9M | 6,636 | 1,894 |
| Texas | $1.8M | 7,038 | 1,977 |
| Pennsylvania | $1.8M | 7,862 | 1,737 |
| California | $1.7M | 6,630 | 1,913 |
| New York | $1.5M | 6,373 | 1,657 |
| North Carolina | $1.3M | 4,804 | 1,198 |
| Michigan | $1.2M | 4,175 | 1,135 |
| Ohio | $1.2M | 4,330 | 1,161 |
| Georgia | $941.7K | 3,459 | 915 |
| Maryland | $701.1K | 2,678 | 756 |
| South Carolina | $653.4K | 2,616 | 679 |
| Puerto Rico | $616.5K | 2,420 | 579 |
| Indiana | $604.2K | 2,137 | 585 |
| Illinois | $602.9K | 2,474 | 673 |
| Alabama | $590.7K | 1,759 | 469 |
| Connecticut | $570.8K | 2,240 | 618 |
| Virginia | $555.1K | 2,383 | 593 |
| Tennessee | $519.5K | 2,080 | 517 |
| Missouri | $397.0K | 1,764 | 417 |
| Massachusetts | $353.4K | 1,820 | 447 |
| Louisiana | $319.3K | 1,235 | 327 |
| Wisconsin | $314.5K | 1,049 | 269 |
| Oklahoma | $280.2K | 1,006 | 279 |
| Kansas | $269.6K | 1,425 | 277 |
| Kentucky | $250.5K | 1,015 | 262 |
| Hawaii | $226.3K | 1,274 | 355 |
| Colorado | $190.7K | 604 | 183 |
| Arkansas | $188.5K | 712 | 185 |
| Delaware | $173.1K | 617 | 177 |
| Arizona | $165.5K | 657 | 211 |
| Washington | $150.2K | 634 | 188 |
| West Virginia | $137.9K | 463 | 140 |
| Mississippi | $116.1K | 620 | 157 |
| Nevada | $87.6K | 378 | 108 |
| Oregon | $81.4K | 302 | 88 |
| District of Columbia | $78.7K | 288 | 90 |
| New Hampshire | $73.9K | 304 | 82 |
| Minnesota | $68.4K | 281 | 84 |
| Iowa | $65.2K | 363 | 95 |
| Maine | $61.3K | 246 | 72 |
| Rhode Island | $56.9K | 249 | 66 |
| Alaska | $54.5K | 131 | 42 |
| Nebraska | $52.9K | 227 | 60 |
| Utah | $52.2K | 179 | 58 |
| New Mexico | $49.5K | 180 | 58 |
| Idaho | $26.5K | 109 | 33 |
| Vermont | $24.7K | 93 | 24 |
| Wyoming | $18.8K | 58 | 16 |
| North Dakota | $13.0K | 62 | 18 |
| South Dakota | $12.1K | 50 | 17 |
| Montana | $10.2K | 50 | 17 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.